{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:35:55Z","timestamp":1790613355501,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009572","name":"Universit\u00e4t St. Gallen","doi-asserted-by":"publisher","award":["This study was funded by the School of Medicine at the University of St. Gallen in Switzerland under grant number 2300380."],"award-info":[{"award-number":["This study was funded by the School of Medicine at the University of St. Gallen in Switzerland under grant number 2300380."]}],"id":[{"id":"10.13039\/100009572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009572","name":"University of St.Gallen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009572","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01148-2","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:37:27Z","timestamp":1749541047000},"page":"569-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2791-0774","authenticated-orcid":false,"given":"Marie","family":"Wosny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2779-5942","authenticated-orcid":false,"given":"Stefanie","family":"Aeppli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-3640","authenticated-orcid":false,"given":"Stefanie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8894-6961","authenticated-orcid":false,"given":"Tobias","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-7794","authenticated-orcid":false,"given":"Christian","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-4923","authenticated-orcid":false,"given":"Janna","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"1148_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1148_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1148_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362.","journal-title":"Eur Urol"},{"key":"1148_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s13193-012-0142-6","volume":"3","author":"M Adhyam","year":"2012","unstructured":"Adhyam M, Gupta AK. A Review on the clinical utility of PSA in cancer prostate. Indian J Surg Oncol. 2012;3:120\u20139.","journal-title":"Indian J Surg Oncol"},{"key":"1148_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/jcm7120565","volume":"7","author":"T Sasaki","year":"2018","unstructured":"Sasaki T, Sugimura Y. The importance of time to prostate-specific antigen (PSA) nadir after primary androgen deprivation therapy in hormone-na\u00efve prostate cancer patients. J Clin Med. 2018;7:565.","journal-title":"J Clin Med"},{"key":"1148_CR6","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365\u201380.","journal-title":"Transl Androl Urol."},{"key":"1148_CR7","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Campos F, Conde-Moreno A, Barrado Los Arcos M, G\u00f3mez-Caama\u00f1o A, Garc\u00eda-G\u00f3mez R, Herv\u00e1s Mor\u00f3n A. Treatment landscape of nonmetastatic castration-resistant prostate cancer: a window of opportunity. J Pers Med. 2021;11:1190.","DOI":"10.3390\/jpm11111190"},{"key":"1148_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150\u20138.","journal-title":"Eur Urol"},{"key":"1148_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235\u201346.","journal-title":"N Engl J Med"},{"key":"1148_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","volume":"96","author":"DM Moreira","year":"2016","unstructured":"Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171\u20136.","journal-title":"Urology"},{"key":"1148_CR11","doi-asserted-by":"publisher","first-page":"1240864","DOI":"10.3389\/fonc.2023.1240864","volume":"13","author":"D Leaning","year":"2023","unstructured":"Leaning D, Kaur G, Morgans AK, Ghouse R, Mirante O, Chowdhury S. Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews. Front Oncol. 2023;13:1240864.","journal-title":"Front Oncol"},{"key":"1148_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(20)39898-7\/fulltext","journal-title":"Ann Oncol"},{"key":"1148_CR13","unstructured":"National Comprehensive Cancer Network. NCCN guidelines on prostate cancer. Plymouth Meeting, PA: NCCN; 2023. https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/10\/article-p1067.xml?content=fullhtml-7350"},{"key":"1148_CR14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"1148_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719\u201332.","journal-title":"N Engl J Med"},{"key":"1148_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1148_CR17","first-page":"8048","volume":"22","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, et al. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015;22:8048\u201355.","journal-title":"Can J Urol"},{"key":"1148_CR18","first-page":"203","volume":"17","author":"CM Pieczonka","year":"2015","unstructured":"Pieczonka CM, Telonis D, Mouraviev V, Albala D. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: considerations for clinical practice. Rev Urol. 2015;17:203\u201310.","journal-title":"Rev Urol"},{"key":"1148_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"1148_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"1148_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"1148_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738\u201346.","journal-title":"Lancet Oncol"},{"key":"1148_CR23","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.21037\/tau-20-1341","volume":"10","author":"C Maurice Dror","year":"2021","unstructured":"Maurice Dror C, Chi KN, Khalaf DJ. Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer\u2014a narrative review. Transl Androl Urol. 2021;10:3931\u201345.","journal-title":"Transl Androl Urol."},{"key":"1148_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.euros.2022.08.018","volume":"45","author":"A Bjartell","year":"2022","unstructured":"Bjartell A, Costa L, Kramer G, Zurawski B, Galli L, Werbrouck P, et al. Real-world treatment sequencing in patients with metastatic castration-resistant prostate cancer: results from the prospective, international, observational prostate cancer registry. Eur Urol Open Sci. 2022;45:12\u201322.","journal-title":"Eur Urol Open Sci."},{"key":"1148_CR25","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","volume":"16","author":"D Lorente","year":"2015","unstructured":"Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16:e279-292.","journal-title":"Lancet Oncol"},{"key":"1148_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88\u201399.","journal-title":"Eur Urol"},{"key":"1148_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/biomedicines9091247","volume":"9","author":"I Henr\u00edquez","year":"2021","unstructured":"Henr\u00edquez I, Roach M, Morgan TM, Bossi A, G\u00f3mez JA, Abuchaibe O, et al. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines. 2021;9:1247.","journal-title":"Biomedicines."},{"key":"1148_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1148_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1148_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1148_CR31","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.21037\/tau-20-1118","volume":"10","author":"S Ong","year":"2021","unstructured":"Ong S, O\u2019Brien J, Medhurst E, Lawrentschuk N, Murphy D, Azad A. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer\u2014a narrative review. Transl Androl Urol. 2021;10:3918\u201330.","journal-title":"Transl Androl Urol."},{"key":"1148_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.843110","volume":"13","author":"M-K Chen","year":"2022","unstructured":"Chen M-K, Liang Z-J, Luo D-S, Xue K-Y, Liao D-Y, Li Z, et al. Abiraterone, orteronel, enzalutamide and docetaxel: sequential or combined therapy? Front Pharmacol. 2022;13: 843110.","journal-title":"Front Pharmacol"},{"key":"1148_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103\u201311.","journal-title":"Intern Emerg Med"},{"key":"1148_CR34","doi-asserted-by":"publisher","unstructured":"Castro E, Ellis J, Craigie S, Haltner A, Nazari J, Niyazov A, et al. Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer. Oncologist. 2024;oyae237. https:\/\/doi.org\/10.1093\/oncolo\/oyae237","DOI":"10.1093\/oncolo\/oyae237"},{"key":"1148_CR35","doi-asserted-by":"publisher","unstructured":"Ai J, Jian L, Wen X, Huo X, Yang X, Jiang J, et al. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Clin Transl Oncol. 2024;26:2559-2571. https:\/\/doi.org\/10.1007\/s12094-024-03506-4","DOI":"10.1007\/s12094-024-03506-4"},{"key":"1148_CR36","doi-asserted-by":"publisher","first-page":"1378993","DOI":"10.3389\/fonc.2024.1378993","volume":"14","author":"D Zhang","year":"2024","unstructured":"Zhang D, Weng H, Zhu Z, Gong W, Ma Y. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review. Front Oncol. 2024;14:1378993.","journal-title":"Front Oncol"},{"key":"1148_CR37","doi-asserted-by":"publisher","first-page":"1290990","DOI":"10.3389\/fphar.2023.1290990","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Deng X, Wen Z, Huang J, Wang C, Chen C, et al. Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1290990.","journal-title":"Front Pharmacol"},{"key":"1148_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104286","volume":"196","author":"X Xiong","year":"2024","unstructured":"Xiong X, Zhang S, Zheng W, Liao X, Yang J, Xu H, et al. Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis. Crit Rev Oncol Hematol. 2024;196: 104286.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1148_CR39","doi-asserted-by":"publisher","first-page":"1134719","DOI":"10.3389\/fendo.2023.1134719","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, Wang Q, Pan Y, et al. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1134719.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"1148_CR40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg"},{"key":"1148_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"1148_CR42","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4 (updated August 2023). 2023. www.training.cochrane.org\/handbook. Accessed 29 Apr 2024."},{"key":"1148_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13643-016-0368-4","volume":"5","author":"H Pedder","year":"2016","unstructured":"Pedder H, Sarri G, Keeney E, Nunes V, Dias S. Data extraction for complex meta-analysis (DECiMAL) guide. Syst Rev. 2016;5:212.","journal-title":"Syst Rev"},{"key":"1148_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1148_CR45","unstructured":"WebPlotDigitizer - Copyright 2010-2024 Ankit Rohatgi. https:\/\/apps.automeris.io\/wpd4\/. Accessed 30 May 2024."},{"key":"1148_CR46","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2024. https:\/\/www.r-project.org\/."},{"key":"1148_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"1148_CR48","first-page":"285","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth. Methods. 2012;3:285\u201399.","journal-title":"Methods"},{"key":"1148_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7:80\u201393.","journal-title":"Res Synth Methods."},{"key":"1148_CR50","unstructured":"van Valkenhoef G, Kuiper J. gemtc: Network meta-analysis using Bayesian methods. 2023. https:\/\/CRAN.R-project.org\/package=gemtc."},{"key":"1148_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349: g5630.","journal-title":"BMJ"},{"key":"1148_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344.","journal-title":"J Clin Epidemiol"},{"key":"1148_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","volume":"150","author":"HJ Sch\u00fcnemann","year":"2022","unstructured":"Sch\u00fcnemann HJ, Neumann I, Hultcrantz M, Brignardello-Petersen R, Zeng L, Murad MH, et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. J Clin Epidemiol. 2022;150:225\u201342.","journal-title":"J Clin Epidemiol"},{"key":"1148_CR54","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"1148_CR55","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"1148_CR56","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35:3189\u201397.","journal-title":"J Clin Oncol"},{"key":"1148_CR57","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Randomized phase 3 trial of abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"1148_CR58","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"1148_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(13)70294-8","volume":"14","author":"DI Quinn","year":"2013","unstructured":"Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14:893\u2013900.","journal-title":"Lancet Oncol"},{"key":"1148_CR60","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fl\u00e9chon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760\u20138.","journal-title":"Lancet Oncol"},{"key":"1148_CR61","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1002\/cncr.27674","volume":"118","author":"JB Nelson","year":"2012","unstructured":"Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012;118:5709\u201318.","journal-title":"Cancer"},{"key":"1148_CR62","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","volume":"31","author":"K Fizazi","year":"2013","unstructured":"Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31:1740\u20137.","journal-title":"J Clin Oncol"},{"key":"1148_CR63","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"1148_CR64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","volume":"16","author":"DP Petrylak","year":"2015","unstructured":"Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16:417\u201325.","journal-title":"Lancet Oncol"},{"key":"1148_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40\u20137.","journal-title":"J Clin Oncol"},{"key":"1148_CR66","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","volume":"16","author":"F Saad","year":"2015","unstructured":"Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16:338\u201348.","journal-title":"Lancet Oncol"},{"key":"1148_CR67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33:723\u201331.","journal-title":"J Clin Oncol"},{"key":"1148_CR68","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1148_CR69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejca.2018.10.005","volume":"107","author":"OW Hakenberg","year":"2019","unstructured":"Hakenberg OW, Perez-Gracia JL, Castellano D, Demkow T, Ali T, Caffo O, et al. Randomised phase II study of second-line olaratumab with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;107:186\u201395.","journal-title":"Eur J Cancer"},{"key":"1148_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153\u201363.","journal-title":"Lancet Oncol"},{"key":"1148_CR71","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard A-C, Kim CS, G\u00e9czi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35:3198\u2013206.","journal-title":"J Clin Oncol"},{"key":"1148_CR72","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:1051\u201361.","journal-title":"J Clin Oncol"},{"key":"1148_CR73","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/1078-0432.CCR-15-2512","volume":"22","author":"M Hussain","year":"2016","unstructured":"Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K, et al. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2016;22:3192\u2013200.","journal-title":"Clin Cancer Res"},{"key":"1148_CR74","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10637-018-0630-9","volume":"36","author":"P Monk","year":"2018","unstructured":"Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, et al. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018;36:919\u201326.","journal-title":"Invest New Drugs"},{"key":"1148_CR75","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","volume":"34","author":"M Smith","year":"2016","unstructured":"Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34:3005\u201313.","journal-title":"J Clin Oncol"},{"key":"1148_CR76","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34:2098\u2013106.","journal-title":"J Clin Oncol"},{"key":"1148_CR77","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.22.02394","volume":"41","author":"MJ Morris","year":"2023","unstructured":"Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, et al. Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer (Alliance A031201 Trial). J Clin Oncol. 2023;41:3352\u201362.","journal-title":"J Clin Oncol"},{"key":"1148_CR78","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","volume":"36","author":"G Attard","year":"2018","unstructured":"Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, et al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018;36:2639\u201346.","journal-title":"J Clin Oncol"},{"key":"1148_CR79","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, et al. Efficacy and safety of autologous dendritic cell\u2013based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial. JAMA Oncol. 2022;8:546\u201352.","journal-title":"JAMA Oncol"},{"key":"1148_CR80","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","volume":"22","author":"F Saad","year":"2021","unstructured":"Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021;22:1541\u201359.","journal-title":"Lancet Oncol"},{"key":"1148_CR81","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.20.02759","volume":"39","author":"SR Denmeade","year":"2021","unstructured":"Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, et al. TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J Clin Oncol. 2021;39:1371\u201382.","journal-title":"J Clin Oncol"},{"key":"1148_CR82","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S1470-2045(22)00560-5","volume":"23","author":"AS Merseburger","year":"2022","unstructured":"Merseburger AS, Attard G, \u00c5str\u00f6m L, Matveev VB, Bracarda S, Esen A, et al. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol. 2022;23:1398\u2013408.","journal-title":"Lancet Oncol"},{"key":"1148_CR83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131\u201342.","journal-title":"Lancet"},{"key":"1148_CR84","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506\u201318.","journal-title":"N Engl J Med"},{"key":"1148_CR85","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1200\/JCO.22.01726","volume":"41","author":"S Gillessen","year":"2023","unstructured":"Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, et al. Darolutamide maintenance in patients with metastatic castration-resistant prostate cancer with nonprogressive disease after taxane treatment (SAKK 08\/16). J Clin Oncol. 2023;41:3608\u201315.","journal-title":"J Clin Oncol"},{"key":"1148_CR86","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide vs enzalutamide alone in metastatic castration-resistant prostate cancer: a randomised phase 3 trial. Nat Med. 2022;28:144\u201353.","journal-title":"Nat Med"},{"key":"1148_CR87","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303.","journal-title":"Lancet"},{"key":"1148_CR88","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"1148_CR89","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 Trial. J Clin Oncol. 2023;41:3839\u201350.","journal-title":"J Clin Oncol"},{"key":"1148_CR90","unstructured":"Agarwal N, Azad AA, Carles J, Oudard S, Saad F, Merseburger A, et al. Cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC): primary analyses from the phase 3 CONTACT-02 study. ASCO GU 2024. San Francisco, CA; 2024. https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2024\/asco-gu-2024-press-releases\/149302-exelixis-announces-detailed-results-of-phase-3-contact-02-pivotal-trial-evaluating-cabozantinib-in-combination-with-atezolizumab-in-metastatic-castration-resistant-prostate-cancer-presented-at-asco-gu-2024.html."},{"key":"1148_CR91","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-21-2326","volume":"28","author":"CJ Sweeney","year":"2022","unstructured":"Sweeney CJ, Percent IJ, Babu S, Cultrera JL, Mehlhaff BA, Goodman OB, et al. Phase Ib\/II study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28:2237\u201347.","journal-title":"Clin Cancer Res"},{"key":"1148_CR92","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235\u201348.","journal-title":"Ann Oncol"},{"key":"1148_CR93","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/1389450116666150907101044","volume":"17","author":"R Assi","year":"2016","unstructured":"Assi R, Temraz S, Shamseddine A, Mukherji D. New compounds targeting the androgen receptor for treatment of advanced prostate cancer. Curr Drug Targets. 2016;17:290\u2013302.","journal-title":"Curr Drug Targets"},{"key":"1148_CR94","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausov\u00e1 J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"1148_CR95","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00280-010-1538-z","volume":"67","author":"C Chouaid","year":"2011","unstructured":"Chouaid C, Nathan F, Pemberton K, Morris T. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2011;67:1203\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1148_CR96","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/biomedicines9081042","volume":"9","author":"FE von Eyben","year":"2021","unstructured":"von Eyben FE, Kairemo K, Paller C, Hoffmann MA, Paganelli G, Virgolini I, et al. 177Lu-PSMA radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines. 2021;9:1042.","journal-title":"Biomedicines."},{"key":"1148_CR97","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clgc.2020.02.005","volume":"18","author":"AE Hird","year":"2020","unstructured":"Hird AE, Magee DE, Bhindi B, Ye XY, Chandrasekar T, Goldberg H, et al. A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2020;18:343\u201350.","journal-title":"Clin Genitourin Cancer"},{"key":"1148_CR98","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","volume":"6","author":"B Cao","year":"2023","unstructured":"Cao B, Kim M, Reizine NM, Moreira DM. Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis. Eur Urol Oncol. 2023;6:237\u201350.","journal-title":"Eur Urol Oncol."},{"key":"1148_CR99","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W, Shaw GK, Valen\u00e7a L, Bernard B, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018;78:889\u201395.","journal-title":"Prostate"},{"key":"1148_CR100","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/bmjebm-2022-111931","volume":"28","author":"RD Riley","year":"2023","unstructured":"Riley RD, Dias S, Donegan S, Tierney JF, Stewart LA, Efthimiou O, et al. Using individual participant data to improve network meta-analysis projects. BMJ Evid Based Med. 2023;28:197\u2013203.","journal-title":"BMJ Evid Based Med."},{"key":"1148_CR101","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jrsm.1305","volume":"9","author":"J Leahy","year":"2018","unstructured":"Leahy J, O\u2019Leary A, Afdhal N, Gray E, Milligan S, Wehmeyer MH, et al. The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection. Res Synth Methods. 2018;9:441\u201369.","journal-title":"Res Synth Methods."},{"key":"1148_CR102","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12874-020-01198-2","volume":"21","author":"S Kanters","year":"2021","unstructured":"Kanters S, Karim ME, Thorlund K, Anis A, Bansback N. When does the use of individual patient data in network meta-analysis make a difference? A simulation study. BMC Med Res Methodol. 2021;21:21.","journal-title":"BMC Med Res Methodol"},{"key":"1148_CR103","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/bmjebm-2022-112024","volume":"28","author":"AA Veroniki","year":"2023","unstructured":"Veroniki AA, Stewart LA, Le SPC, Clarke M, Tricco AC, Straus SE. Retrieval barriers in individual participant data reviews with network meta-analysis. BMJ Evid Based Med. 2023;28:119\u201325.","journal-title":"BMJ Evid Based Med."},{"key":"1148_CR104","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jrsm.1160","volume":"6","author":"TPA Debray","year":"2015","unstructured":"Debray TPA, Moons KGM, van Valkenhoef G, Efthimiou O, Hummel N, Groenwold RHH, et al. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods. 2015;6:293.","journal-title":"Res Synth Methods."},{"key":"1148_CR105","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/sim.5442","volume":"31","author":"P Saramago","year":"2012","unstructured":"Saramago P, Sutton AJ, Cooper NJ, Manca A. Mixed treatment comparisons using aggregate and individual participant level data. Stat Med. 2012;31:3516\u201336.","journal-title":"Stat Med"},{"key":"1148_CR106","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12874-022-01657-y","volume":"22","author":"J Singh","year":"2022","unstructured":"Singh J, Gsteiger S, Wheaton L, Riley RD, Abrams KR, Gillies CL, et al. Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials. BMC Med Res Methodol. 2022;22:186.","journal-title":"BMC Med Res Methodol"},{"key":"1148_CR107","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565\u201374.","journal-title":"Med Decis Making"},{"key":"1148_CR108","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/0272989X221143058","volume":"43","author":"K Chalkou","year":"2023","unstructured":"Chalkou K, Vickers AJ, Pellegrini F, Manca A, Salanti G. Decision curve analysis for personalized treatment choice between multiple options. Med Decis Making. 2023;43:337\u201349.","journal-title":"Med Decis Making"},{"key":"1148_CR109","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12874-020-00964-6","volume":"20","author":"M Ventresca","year":"2020","unstructured":"Ventresca M, Sch\u00fcnemann HJ, Macbeth F, Clarke M, Thabane L, Griffiths G, et al. Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Med Res Methodol. 2020;20:113.","journal-title":"BMC Med Res Methodol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01148-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:56:17Z","timestamp":1757192177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01148-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01148-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"20 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by University of St.Gallen. This study was funded by the School of Medicine at the University of St.Gallen in Switzerland under Grant number 2300380.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SA has received compensation from Bristol Myers Squibb (advisory board, institutional), Merck (advisory board, speakers\u2019 bureau, institutional), Pfizer (advisory board, speakers\u2019 bureau, institutional), and Pierre-Fabre (travel support, institutional). SF has received compensation from Ipsen (advisory board, institutional), Janssen (speakers\u2019 bureau, institutional), Bayer (travel support), MSD (research funding), Astellas (research funding), and Amgen (advisory role, institutional). TP has received travel support from Janssen and AbbVie. CR has received compensation from Pfizer (advisory board, institutional), Bristol Myers Squibb (advisory board, institutional), and MSD Oncology (advisory board, institutional). MW and JH have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"This study was deemed exempt from formal review and approval by the ethics committee of the University of St. Gallen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MW: Conceptualization, methodology, software, validation, formal analysis, investigation, data curation, visualization, project administration, writing \u2013 original draft, writing \u2013 review and editing. SA: Methodology, validation, formal analysis, investigation, writing \u2013 review and editing. SF: Investigation, validation, writing \u2013 review and editing. TP: Investigation, validation, writing \u2013 review and editing. CR: Conceptualization, investigation, validation, supervision, funding acquisition, project administration, writing \u2013 review and editing. JH: Conceptualization, investigation, validation, supervision, funding acquisition, writing \u2013 review and editing. All authors reviewed the results and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}